辛伐他汀对肾移植后高脂血症患者RANTES及其受体CCR5mRNA表达的影响

《辛伐他汀对肾移植后高脂血症患者RANTES及其受体CCR5mRNA表达的影响》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、辛伐他汀对肾移植后高脂血症患者RANTES及其受体CCR5mRNA表达的影响作者：史艳玲,邹和群,王玉新,徐琴君,唐孝达【关键词】,肾移植EffectofsimvastatinonexpressionofRANTESanditsreceptorCCR5mRNAinrenaltransplantrecipientswithhyperlipidemia　　【Abstract】AIM:TostudywhetherhyperlipidemiaafterrenaltransplantationisrelatedtotheexpressionofRANTES(regulatedona

2、ctivationnormalTcellexpressedandsecreted)anditsreceptorCCR5(chemokinereceptor5)mRNAinperipheralmonocytecells(PMCs)andtoexploreitstherapy.METHODS:Renalrecipientsweredividedintonormallipidemiagroup(n=30)andhyperlipidemiagroup(n=30)accordingtotheserumlipidlevel6-8monthsaftertransplantation.T

3、hepatientsinthehyperlipidemiagroupweretreatedwithsimvastatinfor1.5months(1.5monthtreatmentgroup)or3months(3monthtreatmentgroup).Thecontrolgroupconsistedof30healthysubjects.9Serumtotalcholesterol(TC),triglyceride(TG),lowdensitylipoprotein(LDL),highdensitylipoprotein(HDL)weremeasuredandRTPC

4、RwasusedtodetecttheexpressionofRANTESandCCR5mRNAinPMCs.RESULTS:Therenalfunctionofallthepatientswasnormal.TC,TG,LDLandexpressionofRANTESandCCR5mRNAinthenormallipidemiagroupwerelowerthanthoseinthehyperlipidemiagroup,buthigherthanthoseincontrolgroup(P<0.05),andthosein3monthtreatmentgroupw

5、eresignificantlylowerthanthosein1.5monthtreatmentgroup(P<0.05).CONCLUSION:TheexpressionofRANTESandCCR5mRNAisinvolvedintheearlystagechronicinjuryofkidneyallografts.HyperlipidemiacanstrengthentheincreasedexpressionofRANTESandCCR5mRNA.SimvastatincanreducetheexpressionofRANTESandCCR5mRNAin

6、thekidneytransplantrecipientswithhyperlipidemia.　　【Keywords】kidneytransplantation；hyperlipidemia；RANTES；RTPCR；simvastatin　　【摘要】目的:探讨肾移植术后高脂血症患者外周血RANTES(regulatedonactivationnormalTcellexpressedandsecreted)及其受体CCR5(chemokinereceptor5)mRNA表达及治疗.9方法:根据患者肾移植术后6~8mo的血脂水平分血脂正常组（n=30）和血脂增高组（n=3

7、0），血脂增高组又根据辛伐他汀治疗时间分1.5mo治疗组（n=30）和3mo治疗组（n=30），并设正常对照组（n=30），利用RTPCR检测各组患者外周血RANTES和CCR5mRNA表达水平.结果:各组肾功能正常，胆固醇酯，三酰甘油，低密度脂蛋白水平均按对照组，血脂正常组，血脂增高组顺序递增(P<0.05)，3mo治疗组较1.5mo治疗组有显著降低(P<0.05)；RANTES及其受体CCR5mRNA表达水平按对照组，血脂正常组，血脂增高组顺序递增，1.5mo治疗组和3mo治疗组均较血脂增高组有显著降低（P&l